DUSP1 and neoplasm: The DUSP1/6 inhibitor BCI reduces cell viability in a dose- and time-dependent manner in a wide variety of tumor models, acting as an anti-tumorigenic agent [47–49], although it also exhibits pro-tumorigenic activity in other cellular models [50].